31 reports

  • DERMATOLOGY THERAPEUTICS MARKET, GLOBAL, REVENUE FORECAST FOR COSENTYX ($BN),
  • DERMATOLOGY THERAPEUTICS MARKET, GLOBAL, APPROVED DERMATOLOGY INDICATIONS FOR

The atopic march: progression from atopic dermatitis to allergic rhinitis and asthma.

  • Dermatology
  • World
  • AbbVie Inc.
  • Allergan plc
  • Amgen Inc.
  • DERMATOLOGY THERAPEUTICS MARKET, GLOBAL, REVENUE FORECAST FOR IXEKIZUMAB

The atopic march: progression from atopic dermatitis to allergic rhinitis and asthma.

  • Dermatology
  • World
  • Market Size
  • Amgen Inc.
  • Biologics, Inc.
  • Dermatology Therapeutics Market, Global, Pipeline Programs Targeting CCL11, 2017
  • Dermatology Therapeutics Market, Global, Pipeline Programs Targeting Voltage-Gated Channel Subfamily A Member 3, 2017

New drugs and targets for asthma and COPD.

  • Dermatology
  • World
  • Market Size
  • Allergan plc
  • Apricus Biosciences, Inc.

NEMOLIZUMAB (CHUGAI PHARMACEUTICALS) LEBRIKIZUMAB IS A MOAB DESIGNED TO SPECIFICALLY BLOCK THE ACTION OF IL-##; IL-## IS A CYTOKINE THAT IS A KEY CONTRIBUTOR TO INFLAMMATION IN MANY DISEASES - ATOPIC DERMATITIS, ASTHMA, CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD AND IDIOPATHIC PULMONARY FI

  • Dermatology
  • World
  • Forecast
  • Allergan plc
  • Valeant Pharmaceuticals International, Inc.

In September 2012, GlaxoSmithKline initiated a Phase II safety and pharmacokinetic study of Mechanism Of Action Licensing and Collaboration Phase I - Trial Details Phase II - Trial Details umeclidinium in adolescent asthma subjects to evaluate ## once-daily doses of umeclidinium (GSK##;

  • Dermatology
  • United States
  • Allergan plc
  • Anterios, Inc.
  • Brickell Biotech, Inc.
  • 5.2 ABBREVIATIONS

Omalizumab beyond asthma.

  • Dermatology
  • Anacor Pharmaceuticals, Inc.
  • Astellas Pharma Inc.
  • GlobalData's company
  • Regeneron Pharmaceuticals, Inc.

It is in Phase II stage of development for palmar and axillary hyperhidrosis (as topical formulation) and asthma (as an inhalational formulation).

  • Dermatology
  • United States
  • Product Initiative
  • Supply
  • Dermira, Inc.
  • Clinical Trial profile. 291 Trial Title
  • Clinical Trial profile. 643 Trial Title

Administered for ## Months in Preventing the Onset of Asthma in ## to ## Months Old Children Who Suffer From Atopic Dermatitis and Are Sensitized to Grass Pollen and / or House Dust Mite Allergens Prevention of Asthma with Levocetirizine ## Month Treatment in Infants (## - ##

  • Dermatological Condition
  • Dermatology
  • Drug Discovery And Development
  • World
  • Novartis AG
  • Clinical Trial profile. 813 Trial Title
  • Official Title

Administered for ## Months in Preventing the Onset of Asthma in ## to ## Months Old Children Who Suffer From Atopic Dermatitis and Are Sensitized to Grass Pollen and / or House Dust Mite Allergens Prevention of Asthma with Levocetirizine ## Month Treatment in Infants (## - ##

  • Dermatological Condition
  • Dermatological Treatment
  • Dermatology
  • World
  • Novartis AG
  • Target
  • Clinical Trial profile. 570 Trial Title

Additionally, interim safety and efficacy data will be presented from a Phase ## long-term open-label study of DUPIXENT monotherapy for uncontrolled moderate-to-severe AD at the Annual Meeting of the American Academy of Asthma, Allergy, and Immunology (AAAAI).

  • Dermatological Condition
  • Dermatology
  • Drug Discovery And Development
  • World
  • Novartis AG

The royalty rate on net sales for the COPD indication product would be the same as the asthma indication product.

  • Dermatology
  • Endocrine Disease
  • World
  • Deals & Alliance
  • AstraZeneca PLC
  • Target

In addition to AD, Dupixent is being evaluated in asthma, nasal polyposis and eosinophilic esophagitis.

  • Clinical Trial
  • Dermatology
  • Pharmaceutical
  • World
  • Product Initiative

The company' s ASM## product is used in the treatment of asthma, and orbital dry powder inhailer is used to deliver high dosage drugs to the respiratory tract.

  • Dermatology
  • United States
  • World
  • Product Initiative
  • RXi Pharmaceuticals Corporation

Acne can significantly impact patients' quality of life, resulting in social, psychological and emotional impairments that are comparable to those reported by patients with epilepsy, asthma, diabetes or arthritis.

  • Acne Treatment
  • Dermatology
  • World
  • Market Size
  • Foamix Ltd.

EP-## IN PRECLINICAL DEVELOPMENT FOR SEVERE, ALLERGIC ASTHMA.

  • Anti-Infective
  • Dermatology
  • Pharmaceutical
  • United States
  • Product Initiative

EP-## IN PRECLINICAL DEVELOPMENT FOR SEVERE, ALLERGIC ASTHMA.

  • Dermatology
  • Hospital
  • United States
  • Product Initiative
  • Cellceutix Corporation

It was also under development for the treatment of cognitive impairment associated with schizophrenia (CIAS), chronic obstructive pulmonary disease, asthma, allergic asthma, nonalcoholic steatohepatitis, type ## diabetes (T##D), plaque psoriasis, bronchial asthma and atopic

  • Dermatology
  • Europe
  • Spain
  • Company Financials
  • Almirall, S.A.
  • Official Title
  • Official Title

C/ A Dermatology Atopic Dermatitis, Eczema Completed Other Interventional VU University Medical Center ## Jun 2012 ## Mar 2015 ## ## ## Asthma, a Disease Due to a Lack of Bacterial Infections in Childhood Asthma, a Disease Due to a Lack of Bacterial Infections in Childhood GDCT##

  • Clinical Trial
  • Dermatological Condition
  • Dermatology
  • World
  • Novartis AG

THE COMPANY' S ASM## PRODUCT IS USED IN THE TREATMENT OF ASTHMA, AND ORBITAL DRY POWDER INHAILER IS USED TO DELIVER HIGH DOSAGE DRUGS TO THE RESPIRATORY TRACT.

  • Ambulatory Care
  • Dermatology
  • Canada
  • United States
  • Valeant Pharmaceuticals International, Inc.

Reddy' s Laboratories Ltd ## Dec 2005 ## Feb 2006 Trichuris Suis Ova Therapy for Mild to Moderate Peanut and Tree Nut Allergy in Adults and Children Trichuris Suis Ova in Peanut and Tree Nut Allergy GDCT## NCT##, FAI-TSO-## Dermatology Angioedema, Asthma, Chronic Urticaria Or

  • Clinical Trial
  • Dermatology
  • Pharmaceutical
  • World
  • Product Initiative

Its clinical development pipeline includes alectinib and Erlotinib for metastatic non-small cell lung cancer; Anti-ST## for asthma; etrolizumab for ulcerative colitis; atezolizumab for solid tumors and metastatic melanoma; obinutuzumab for non-Hodgkin' s lymphoma; and pertuzumab for brea

  • Dermatological Condition
  • Dermatology
  • United States
  • Company
  • Dermira, Inc.

Asthma, Atopic Dermatitis, Pruritus, Rheumatoid Arthritis Completed Phase I Interventional JNJ-## Johnson & Johnson ## Feb 2010 ## Dec 2010 ## ## ## H## Antagonist Histamine H## Receptor (H##R or AXOR## or G-Protein Coupled Receptor ## or HRH## or GPCR##) A Metabolite Identification,

  • Clinical Trial
  • Dermatology
  • Pharmaceutical
  • World
  • Product Initiative

Asthma, Bone Tumor, Brain Edema, Brain Tumor, Breast Cancer, Bullous Pemphigoid, Chemotherapy Induced Nausea and Vomiting, Chorioretinitis, Chronic Obstructive Pulmonary Disease (COPD), Crohn' s Disease (Regional Enteritis), Cushing' s Syndrome, Dermatitis Herpetiformis (Duhring

  • Autoimmune Disease
  • Dermatology
  • Monoclonal Antibody
  • World
  • Product Initiative

The company' s research resources are focused on asthma, chronic obstructive pulmonary disease (COPD), gastrointestinal disorders, psoriasis and other dermatological conditions.

  • Dermatology
  • United States
  • Company
  • M&A
  • Valeant Pharmaceuticals International, Inc.

Asthma, Chronic Obstructive Pulmonary Disease (COPD), Inflammatory Bowel Disease, Psoriasis, Rheumatoid Arthritis Completed Phase I Interventional FX-##L Funxional Therapeutics Limited (Inactive) Boehringer Ingelheim GmbH ## Jul 2009 ## Somatostatin Receptor Type ## (SRIF## or SSTR##) Agonist

  • Clinical Trial
  • Dermatological Condition
  • Dermatology
  • World
  • Galderma S.A.

Asthma, Chronic Obstructive Pulmonary Disease (COPD), Inflammatory Bowel Disease, Psoriasis, Rheumatoid Arthritis Completed Phase I Interventional FX-##L Funxional Therapeutics Limited (Inactive) Boehringer Ingelheim GmbH ## Jul 2009 ## Somatostatin Receptor Type ## (SRIF## or SSTR##) Agonist

  • Clinical Trial
  • Dermatology
  • World
  • Product Initiative
  • Galderma S.A.

It was demonstrated that beta-glucans could protect against development of asthma in an animal model.

  • Dermatology
  • Healthcare
  • Wound Care
  • United States
  • Product Initiative

Asthma, Chronic Obstructive Pulmonary Disease (COPD), Inflammatory Bowel Disease, Psoriasis, Rheumatoid Arthritis Completed Phase I Interventional FX-##L Funxional Therapeutics Limited (Inactive) Boehringer Ingelheim GmbH ## Jul 2009 ## Somatostatin Receptor Type ## (SRIF## or SSTR##) Agonist

  • Clinical Trial
  • Dermatology
  • World
  • Product Initiative
  • Galderma S.A.

It was demonstrated that beta-glucans could protect against development of asthma in an animal model.

  • Dermatology
  • Type 2 Diabetes
  • United States
  • Company
  • Product Initiative

The company offers oral medication for asthmas, nasal inflammation allergy, peripheral circulatory disturbance and chronic pancreatitis, among others, and injection drugs for acute lung injury, acute pancreatitis, and blood pressure regulators used during surgical operations.

  • Dermatology
  • United States
  • Company
  • M&A
  • Valeant Pharmaceuticals International, Inc.